调强放疗时代下的临床Ⅱ期鼻咽癌研究进展

Research Progress of Stage Ⅱ Nasopharyngeal Carcinoma in IMRT Era

鼻咽癌（NPC）的治疗已步入到了调强放射治疗（IMRT）时代,患者的治愈率及其生存质量（QOL）明显得到了提高,并且其不良反应也明显减轻。早期NPC的首选是放射治疗,但临床Ⅱ期NPC能否受益于放化疗综合治疗,目前尚有争议。另外,亚组分析发现,提高T2N1M0期患者的预后是临床Ⅱ期鼻咽癌研究进展中的瓶颈。

The treatment of nasopharyngeal carcinoma has entered in the era of intensity modulated radiation therapy（IMRT）,which improved cure rate and quality of life and reduced adverse effects significantly. Radiation therapy has become the standard treatment for early stage nasopharyngeal carcinoma,however,controversy still exists regarding whether stage Ⅱ patients can benefit from the combination of radiotherapy with chemotherapy. Besides,subgroup analyses have found that to improve the prognosis of patients in T2 N1 M0 stage is the key problem for research of stage Ⅱ nasopharyngeal carcinoma.